Benzinga | Jun 16, 2021 08:30AM EDT

Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial

* The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ:PSTV) to proceed to the eighth cohort of Phase 1 dose-escalation ReSPECT trial evaluating Rhenium NanoLiposome (RNL) for recurrent glioblastoma.

* The eighth cohort of the ReSPECT trial will implement a 40% increase in total radioactivity.

* The planned infused dose will be 31.2 millicuries in a volume of 12.3 milliliters (increased from 22.3 millicuries and 8.8 milliliters, respectively, used in cohort seven).

* The planned maximum flow rate will not change.

* Price Action: PSTV shares are higher by 2.94% at $2.80 during the premarket session on the last check Wednesday.